Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus

Objective For rheumatoid arthritis (RA), there is no consensus on how to define and assess flare. Variability in flare definitions impairs understanding of findings across studies and limits ability to pool results. The OMERACT RA Flare Group sought to identify domains to define RA flares from patient and healthcare professional (HCP) perspectives. Methods Flare was described as a worsening of disease activity of sufficient intensity and duration to consider a change in therapy. International patients and HCPs participated in separate and combined rounds of Delphi exercises to rate candidate flare domains previously generated in patient focus groups. Core domains were defined as those with ≥70% ratings of being ‘essential’ according to the third/final Delphi exercise. Results The final Delphi included 125 RA patients from 10 countries and 108 HCPs from 23 countries who rated 14 domains. Patients had a mean (±SD) age of 56±12 years and disease duration of 18±12 years. HCPs included physicians from clinical practice/research and industry, allied health providers and researchers with 17±11 years experience. Core domains comprised: pain (93%), function (89%), swollen joints (84%), tender joints (81%), participation (81%), stiffness (79%), patient global assessment (76%) and self-management (75%). Fatigue (68%), which did not reach group consensus, will receive additional consideration. Conclusions As part of the process to develop a measure for RA flare, patients and HCPs agreed on eight core domains. Next steps include identifying items to assess domains and conducting studies to validate and refine a new measure.

[1]  J. Singh,et al.  Developing a provisional definition of flare in patients with established gout. , 2012, Arthritis and rheumatism.

[2]  M. D. de Wit,et al.  The importance of patient participation in measuring rheumatoid arthritis flares , 2012, Annals of the rheumatic diseases.

[3]  M. Calnan,et al.  Utilizing Qualitative Data from Nominal Groups: Exploring the Influences on Treatment Outcome Prioritization with Rheumatoid Arthritis Patients , 2012, Journal of Health Psychology.

[4]  F. Guillemin,et al.  A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: The ‘FLARE’ instrument , 2011, Annals of the rheumatic diseases.

[5]  M. Cross,et al.  'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count--an international patient perspective on flare where medical help is sought. , 2012, Rheumatology.

[6]  V. Strand,et al.  Developing a Construct to Evaluate Flares in Rheumatoid Arthritis: A Conceptual Report of the OMERACT RA Flare Definition Working Group , 2011, The Journal of Rheumatology.

[7]  P. Brooks,et al.  Identifying Preliminary Domains to Detect and Measure Rheumatoid Arthritis Flares: Report of the OMERACT 10 RA Flare Workshop , 2011, The Journal of Rheumatology.

[8]  M. Dougados,et al.  Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative , 2011, Annals of the rheumatic diseases.

[9]  M. D. de Wit,et al.  Treating rheumatoid arthritis to target: the patient version of the international recommendations , 2011 .

[10]  M. Urowitz,et al.  International consensus for a definition of disease flare in lupus , 2011, Lupus.

[11]  P. Tugwell,et al.  American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. , 2011, Arthritis and rheumatism.

[12]  M. D. de Wit,et al.  European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects , 2011, Annals of the Rheumatic Diseases.

[13]  M. Calnan,et al.  Patient perspective of measuring treatment efficacy: The rheumatoid arthritis patient priorities for pharmacologic interventions outcomes , 2010, Arthritis care & research.

[14]  S. Brophy,et al.  Frequency and characteristics of disease flares in ankylosing spondylitis , 2010, Rheumatology.

[15]  V. Strand,et al.  “Flare” and disease worsening in rheumatoid arthritis: Time for a definition , 2009 .

[16]  Mahboob Rahman,et al.  Developing a Standardized Definition for Disease “Flare” in Rheumatoid Arthritis (OMERACT 9 Special Interest Group) , 2009, The Journal of Rheumatology.

[17]  R. Shewchuk,et al.  Toward a valid definition of gout flare: results of consensus exercises using Delphi methodology and cognitive mapping. , 2009, Arthritis and rheumatism.

[18]  M. Dougados,et al.  Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative , 2008, Annals of the rheumatic diseases.

[19]  A. Cieza,et al.  Responsiveness of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[20]  P Tugwell,et al.  Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. , 2008, Arthritis and rheumatism.

[21]  P. Dieppe,et al.  Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration. , 2008, Rheumatology.

[22]  F. Wolfe,et al.  The challenges of determining RA disease activity and remission in clinical practice , 2008, Nature Clinical Practice Rheumatology.

[23]  F. Wolfe,et al.  The problem of rheumatoid arthritis disease activity and remission in clinical practice. , 2008, The Journal of rheumatology.

[24]  M. Suarez‐Almazor,et al.  Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. , 2007, The Journal of rheumatology.

[25]  P. Voulgari,et al.  Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. , 2006, Seminars in arthritis and rheumatism.

[26]  M. Dougados,et al.  Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. , 2005, Rheumatology.

[27]  E. Taal,et al.  Outcomes from the Patient Perspective Workshop at OMERACT 6. , 2003, The Journal of rheumatology.

[28]  A. Calin,et al.  Definition of disease flare in ankylosing spondylitis: the patients' perspective. , 2002, The Journal of rheumatology.

[29]  E. Giannini,et al.  Preliminary definition of disease flare in juvenile rheumatoid arthritis. , 2002, The Journal of rheumatology.

[30]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .

[31]  R. Brook,et al.  Consensus methods: characteristics and guidelines for use. , 1984, American journal of public health.